Patritumab Deruxtecan Withdrawn After Failing to Improve Survival in NSCLC Trial
Pharmaceutical companies Merck and Daiichi Sankyo have withdrawn their regulatory application for patritumab deruxtecan, an antibody-drug conjugate designed to target the HER3 protein, after it failed to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer. The move comes after a topline readout of the Phase III HERTHENA-Lung02 trial … Read more